Effectiveness of combination therapy with intrathecal or intraventricular administration of polymyxin B for hospital-acquired central nervous system infections caused by carbapenem-resistant Acinetobacter baumannii: A retrospective study

被引:0
|
作者
Xu, Chenfeng [1 ,2 ]
Zeng, Fang [1 ,2 ]
Xu, Qiling [1 ,2 ]
Yang, Yu [1 ,2 ]
Zhang, Yu [1 ,2 ]
Shi, Chen [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430022, Peoples R China
[2] Hubei Prov Clin Res Ctr Precis Med Crit Illness, Wuhan, Peoples R China
基金
中国国家自然科学基金;
关键词
Polymyxin B; Intracranial infection; Intrathecal; Intraventricular; Carbapenem-resistant Acinetobacter; baumannii; CARE-ASSOCIATED VENTRICULITIS; CLINICAL-PRACTICE GUIDELINES; GRAM-NEGATIVE BACILLI; MULTIDRUG-RESISTANT; DISEASES SOCIETY; COLISTIN; MENINGITIS; DRAINAGE;
D O I
10.1016/j.ijantimicag.2024.107334
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To evaluate the therapeutic regimen, efficacy and safety of intrathecal or intraventricular (ITH/IVT) administration of polymyxin B for hospital-acquired central nervous system (CNS) infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB). Methods: A retrospective study was undertaken of patients with CNS infections caused by CRAB treated with ITH/IVT combination therapy. The primary outcome was the clinical efficacy of treatment. The secondary outcomes were the bacterial clearance rate and the safety of therapy. Results: In total, 35 patients who received ITH [ n = 13 (37.1%)] or IVT [ n = 22 (62.9%)] polymyxin B as combination therapy were included in this study. The median duration of ITH/IVT polymyxin B therapy was 9 (interquartile range 7-11) days. The overall clinical cure rate and bacterial clearance rate were 77.1% and 85.7%, respectively. No adverse effects considered to be related to ITH/IVT polymyxin B were recorded. Clinical failure was independently associated with an Acute Physiology and Chronic Health Evaluation II score >= 15 [odds ratio (OR) 1.24, 95% confidence interval (CI) 1.05-1.42; P = 0.038] and a Glasgow Coma Scale score <8 (OR 0.69, 95% CI 0.49-0.88; P = 0.029). Early administration ( <4 days of infection onset) of ITH/IVT polymyxin B therapy resulted in a significantly higher clinical cure rate (OR 0.65, 95% CI 0.49- 1.12; P < 0.001), and may reduce the length of treatment and adverse effects. Conclusions: ITH/IVT administration of polymyxin B is a valid alternative for the treatment of CNS infections caused by CRAB. Early use of ITH/IVT polymyxin B can result in greater clinical success. (c) 2024 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页数:7
相关论文
共 20 条
  • [1] Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii
    Chang, Kang
    Wang, Haibo
    Zhao, Jianping
    Yang, Xianghong
    Wu, Bo
    Sun, Wenkui
    Huang, Man
    Cheng, Zhenshun
    Chen, Hong
    Song, Yuanlin
    Chen, Ping
    Chen, Xiangqi
    Gan, Xin
    Ma, Wanli
    Xing, Lihua
    Wang, Yimin
    Gu, Xiaoying
    Zou, Xiaohui
    Cao, Bin
    FRONTIERS IN MEDICINE, 2022, 9
  • [2] Ceftazidime-avibactam-based combination therapy for hospital-acquired central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae
    Zhao, Xiaoyu
    Li, Shirong
    Zhang, Yixin
    Wang, Jue
    Wang, Chuning
    Qin, Xiaohua
    Hu, Fupin
    Wang, Minggui
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 61 (05)
  • [3] Hospital-Acquired Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Observational Study
    Aldali, Hamzah J. J.
    Khan, Azra
    Alshehri, Abdullah A. A.
    Aldali, Jehad A. A.
    Meo, Sultan Ayoub
    Hindi, Ali
    Elsokkary, Emadeldin M. M.
    MICROORGANISMS, 2023, 11 (06)
  • [4] Intrathecal or Intraventricular Tigecycline Therapy for Central Nervous System Infection Associated with Carbapenem-Resistant Klebsiella pneumoniae
    Du, Ning
    Mao, En-Qiang
    Yang, Zhi-Tao
    Qu, Hong-Ping
    Qian, Xian
    Shi, Ying
    Bian, Xiao-Lan
    He, Juan
    Chen, Er-Zhen
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 7219 - 7226
  • [5] Outcomes of adjunctive therapy with intrathecal or intraventricular administration of colistin for post-neurosurgical meningitis and ventriculitis due to carbapenem-resistant acinetobacter baumannii
    Chusri, Sarunyou
    Sakarunchai, Ittichai
    Kositpantawong, Narongdet
    Panthuwong, Siripen
    Santimaleeworagun, Wichai
    Pattharachayakul, Sutthiporn
    Singkhamanan, Kamonnut
    Doi, Yohei
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 51 (04) : 646 - 650
  • [6] Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study
    Russo, Alessandro
    Bassetti, Matteo
    Ceccarelli, Giancarlo
    Carannante, Novella
    Losito, Angela Raffaella
    Bartoletti, Michele
    Corcione, Silvia
    Granata, Guido
    Santoro, Antonella
    Giacobbe, Daniele Roberto
    Peghin, Maddalena
    Vena, Antonio
    Amadori, Francesco
    Segala, Francesco Vladimiro
    Giannella, Maddalena
    Di Caprio, Giovanni
    Menichetti, Francesco
    Del Bono, Valerio
    Mussini, Cristina
    Petrosillo, Nicola
    De Rosa, Francesco Giuseppe
    Viale, Pierluigi
    Tumbarello, Mario
    Tascini, Carlo
    Viscoli, Claudio
    Venditti, Mario
    JOURNAL OF INFECTION, 2019, 79 (02) : 130 - 138
  • [7] Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
    Garcia, Rebeca Carvalho Lacerda
    Rodrigues, Rodrigo Douglas
    Garcia, Ester Carvalho Lacerda
    Rigatto, Maria Helena
    ANTIBIOTICS-BASEL, 2023, 12 (08):
  • [8] Clinical efficacy of ceftazidime/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa
    Xu, Chenfeng
    Zeng, Fang
    Huang, Yifei
    Xu, Qiling
    Yang, Yu
    Gong, Weijing
    Shi, Chen
    Zhang, Yu
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (01)
  • [9] Intraventricular or intrathecal polymyxin B for treatment of post-neurosurgical intracranial infection caused by carbapenem-resistant gram-negative bacteria: a 8-year retrospective study
    Hu, Yangmin
    Li, Danyang
    Zhang, Gensheng
    Dai, Yunjian
    Chen, Meng
    Jiang, Huifang
    Cui, Wei
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (05) : 875 - 884
  • [10] Efficacy of combination therapy with standard-dose carbapenem for treating nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii in intensive care units: A multicentre retrospective propensity score-matched study
    Wang, Sheng-Huei
    Yang, Kuang-Yao
    Sheu, Chau-Chyun
    Lin, Yu -Chao
    Chan, Ming-Cheng
    Feng, Jia-Yih
    Chen, Chia-Min
    Chen, Chih-Yu
    Zheng, Zhe-Rong
    Chou, Yu -Ching
    Peng, Chung-Kan
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (01)